期刊文献+

Prognostic and predictive response factors in colorectal cancer patients:Between hope and reality 被引量:2

Prognostic and predictive response factors in colorectal cancer patients:Between hope and reality
下载PDF
导出
摘要 Colorectal cancer(CRC) represents one of the most commonly diagnosed cancers worldwide.It is the second leading cause of cancer death in Western Countries.In the last decade the survival of patients with metastatic CRC has improved dramatically.Due to the advent of new drugs(irinotecan and oxaliplatin) and target therapies(i.e.,bevacizumab,cetuximab and panitumab),the median overall survival has risen from about 12 mo in the mid nineties to 30 mo recently.Many questions needing of right collocations and more clearness still exist regarding the prognostic factors and the predictive factors of response to therapy.Despite advances in dosing and scheduling of chemotherapy in both adjuvant and advanced settings,and a greater emphasis on early detection,the outlook still remains poor for most patients.Molecular analyses have shown that the natural history of all CRCs is not the same.Individual patients with same stage tumours may have different long term prognosis and response to therapy.In addition,some prognostic variables are likely to be more important than others.Here we review the role of prognostic factors and predictive factors according to the recently published English literature. Colorectal cancer (CRC) represents one of the most commonly diagnosed cancers worldwide. It is the second leading cause of cancer death in Western Countries. In the last decade the survival of patients with metastatic CRC has improved dramatically. Due to the advent of new drugs (irinotecan and oxaliplatin) and target therapies (i.e., bevacizumab, cetuximab and panitumab), the median overall survival has risen from about 12 mo in the mid nineties to 30 mo recently. Many questions needing of right collocations and more clearness still exist regarding the prognostic factors and the predictive factors of response to therapy. Despite advances in dosing and scheduling of chemotherapy in both adjuvant and advanced settings, and a greater emphasis on early detection, the outlook still remains poor for most patients. Molecular analyses have shown that the natural history of all CRCs is not the same. Individual patients with same stage tumours may have different long term prognosis and response to therapy. In addition, some prognostic variables are likely to be more important than others. Here we review the role of prognostic factors and predictive factors according to the recently published English literature.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第41期15049-15059,共11页 世界胃肠病学杂志(英文版)
关键词 Colorectal cancer Prognosis Prognostic factors Therapy METASTASES Molecular analyses Colorectal cancer Prognosis Prognostic factors The
  • 相关文献

参考文献10

  • 1Georgios Karagkounis,Michael S. Torbenson,Hubert D. Daniel,Nilofer S. Azad,Luis A. Diaz,Ross C. Donehower,Kenzo Hirose,Nita Ahuja,Timothy M. Pawlik,Michael A. Choti.Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases[J].Cancer.2013(23)
  • 2Raffaele Di Francia,Raffaella Stefania Siesto,Daniela Valente,Andrea Del Buono,Sergio Pugliese,Sabrina Cecere,Carla Cavaliere,Guglielmo Nasti,Gaetano Facchini,Massimiliano Berretta.Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests[J].Anti-Cancer Drugs.2013(10)
  • 3Sang-Woo Lim,Hye-Ran Kim,Hwan-Young Kim,Jung-Wook Huh,Young-Jin Kim,Jong-Hee Shin,Soon-Pal Suh,Dong-Wook Ryang,Hyeong-Rok Kim,Myung-Geun Shin.Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor[J].Cellular Oncology.2013(4)
  • 4Massimiliano Berretta,Giuseppe Aprile,Guglielmo Nasti,Martina Urbani,Alessandra Bearz,Stefania Lutrino,Luisa Foltran,Laura Ferrari,Renato Talamini,Francesco Fiorica,Arben Lleshi,Vincenzo Canzonieri,Chiara Lestuzzi,Eugenio Borsatti,Rossella Fisichella,Umberto Tirelli.Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients[J].Anti-Cancer Agents in Medicinal Chemistry.2013(9)
  • 5Massimiliano Berretta,Fabrizio Di Benedetto,Raffaele Di Francia,Emanuele Lo Menzo,Sergio Palmeri,Umberto Tirelli,Paolo De Paoli.Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure[J].Anti-Cancer Agents in Medicinal Chemistry.2013(9)
  • 6Fabrizio Di Benedetto,Giuseppe D’Amico,Mario Spaggiari,Umberto Tirelli,Massimiliano Berretta.Onco-Surgical Management of Colo-Rectal Liver Metastases in Older Patients: A New Frontier in the 3<sup>rd</sup> Millennium[J].Anti-Cancer Agents in Medicinal Chemistry.2013(9)
  • 7Pei-Ching Lin,Jen-Kou Lin,Chun-Chi Lin,Huann-Sheng Wang,Shung-Haur Yang,Jeng-Kai Jiang,Yuan-Tzu Lan,Tzu-Chen Lin,Anna Fen-Yau Li,Wei-Shone Chen,Shih-Ching Chang.Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis[J]. International Journal of Colorectal Disease . 2012 (10)
  • 8Tomoya Yokota.Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?[J].Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents).2012(2)
  • 9Massimiliano Berretta,Ernesto Zanet,Guglielmo Nasti,Arben Lleshi,Sergio Frustaci,Francesco Fiorica,Alessandra Bearz,Renato Talamini,Chiara Lestuzzi,Renzo Lazzarini,Rossella Fisichella,Renato Cannizzaro,Rosario Vincenzo Iaffaioli,Salvatore Berretta,Umberto Tirelli.Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)[J].Archives of Gerontology and Geriatrics.2011(2)
  • 10Francesco Fiorica,Massimiliano Berretta,Stefano Ursino,Rossella Fisichella,Arben Lleshi,Gerlando Fiorica,Antonio Stefanelli,Giampaolo Zini,Umberto Tirelli,Antonio Zanghi,Alessandro Cappellani,Salvatore Berretta,Francesco Cartei.Adjuvant radiotherapy on older and oldest breast cancer patients after conservative surgery: A retrospective analysis[J].Archives of Gerontology and Geriatrics.2011(2)

共引文献2

同被引文献33

  • 1Jian-Ming Xu,Yan Wang,Fei-Jiao Ge,Li Lin,Ze-Yuan Liu,Manish R Sharma.Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms[J].World Journal of Gastroenterology,2013,19(24):3899-3903. 被引量:14
  • 2E.A. Eisenhauer,P. Therasse,J. Bogaerts,L.H. Schwartz,D. Sargent,R. Ford,J. Dancey,S. Arbuck,S. Gwyther,M. Mooney,L. Rubinstein,L. Shankar,L. Dodd,R. Kaplan,D. Lacombe,J. Verweij.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. European Journal of Cancer . 2008 (2)
  • 3Peter S. Yoo,Reynold I. Lopez-Soler,Walter E. Longo,Charles H. Cha.Liver Resection for Metastatic Colorectal Cancer in the Age of Neoadjuvant Chemotherapy and Bevacizumab[J].Clinical Colorectal Cancer.2006(3)
  • 4Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet‐Tieulent,Ahmedin Jemal.Global cancer statistics, 2012[J]. CA: A Cancer Journal for Clinicians . 2015 (2)
  • 5Tournigand C,Andre T,Achille E,et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology . 2004
  • 6Freyer G,Rougier P,Bugat R,Droz JP,Marty M,Bleiberg H,Mignard D,Awad L,Herait P,Culine S,Trillet-Lenoir V.Prognostic factors for tumour response progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11)as second-line chemotherapy after 5FU failure.CPT-11F205 F220 F221 and V222 study groups. British Journal of Cancer . 2000
  • 7Meyerhardt Jeffrey A,Kwok Ambrose,Ratain Mark J,McGovren J Patrick,Fuchs Charles S.Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 2004
  • 8Dréanic J,Maillet M,Dhooge M,et al.Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies. Medical Oncology . 2013
  • 9Loupakis F,Yang D,Yau L,Feng S,Cremolini C,Zhang W,Maus MK,Antoniotti C,Langer C,Scherer SJ,Müller T,Hurwitz HI,Saltz L,Falcone A,Lenz HJ.Primary tumor location as a prognostic factor in metastatic colorectal cancer. Journal of the National Cancer Institute . 2015
  • 10Junko Sugatani,Kasumi Yamakawa,Kouich Yoshinari,Takashi Machida,Hitoshi Takagi,Masatomo Mori,Satoru Kakizaki,Tatsuya Sueyoshi,Masahiko Negishi,Masao Miwa.??Identification of a Defect in the UGT1A1 Gene Promoter and Its Association with Hyperbilirubinemia(J)Biochemical and Biophysical Research Communications . 2002 (2)

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部